Apply for grants

Ownership

Our investment activities as well as our ownership of the Novo Group companies are managed by our fully owned subsidiary Novo Holdings A/S. The objective of Novo Holdings A/S is to generate attractive long-term returns on the assets of the Novo Nordisk Foundation (“the Foundation”).

So how does it work?

Novo Holdings A/S

Novo Holdings A/S is the holding company for the companies in the Novo Group; Novo Nordisk A/S and Novonesis A/S.

In addition, Novo Holdings A/S manages an investment portfolio with a long-term investment objective. The investment portfolio is comprised of Life Science Investments and Capital Investments.

Through its Seed, Venture, Growth, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

Capital Investments encompasses a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets.

Ownership and majority holding in Novo Nordisk A/S and Novonesis A/S

In accordance with the Foundation’s Articles of Association, the Foundation is obligated to maintain a controlling interest in Novo Nordisk A/S and Novonesis A/S, the Novo Group’s two large publicly listed companies.

At the end of 2025, Novo Holdings A/S owned A (multiple voting rights) and B (ordinary) shares in Novo Nordisk A/S equivalent to about 28.1% of the share capital and about 77.3% of the votes and A and B shares in Novonesis A/S equivalent to about 25.5% of the share capital and about 63.4% of the votes. The A (multiple voting rights) shares in the two companies are unlisted and are not traded. In both Novo Nordisk A/S and Novonesis A/S, the A shares have voting rights that are 10 times greater than those of the B (ordinary) shares.

Read more on Novo Holdings A/S’ website.

How do we carry out our ownership of Novo Nordisk A/S and Novonesis A/S?

According to the Articles of Association of the Novo Nordisk Foundation,, the Foundation must provide a stable basis for the commercial and research activities of Novo Nordisk A/S and Novonesis A/S. In order to fulfil this objective, the Foundation must maintain a majority of the votes in the form of A shares in both companies. In addition to this, it has been decided that the Foundation should hold at least 25.5% of the two companies’ share capital. The Foundation has given its fully owned subsidiary Novo Holdings A/S mandate to act on its behalf in carrying out the long-term ownership of Novo Nordisk A/S and Novonesis A/S.

In 2025, the Foundation adopted the Novo Group Governance Principles. The purpose of these principles is to ensure good governance between the following entities in the Novo Group:

  • Novo Nordisk Foundation
  • Novo Holdings A/S
  • Novo Nordisk A/S and Novonesis A/S

The governance principles intend to enable the Novo Group entities to fulfil their specific objectives and create a robust system of checks and balances while maintaining an arm’s length relationship with the operating companies. They intend to ensure that no individual, board or entity can exert undue influence or act in a way that unduly prioritises individual interests over those of the Novo Group as a whole and to promote transparency and accountability.

You can read the Governance Principles here.

Additionally, as a permanent owner of Novo Nordisk A/S and Novonesis A/S, the Foundation has formulated several long-term objectives concerning its ownership. The objectives reflect that Novo Nordisk A/S and Novonesis A/S must be global leaders in their respective fields with distinct commercial and research activities. Thus, through its ownership the Foundation seeks, among other things, to support the companies in:

  • realising a shared vision to contribute positively to the lives of people and the sustainability of society;
  • providing engaging and inspiring working environments;
  • generating competitive long-term financial results; and
  • living up to the Novo Charter.

The Foundation emphasises being a responsible, relevant and capable owner, thereby helping to secure the financial capacity of the companies and supporting societal developments that will benefit Novo Nordisk A/S and Novonesis A/S as well as the rest of society. This has concrete implications for the Foundation, for instance in relation to capital reserves and policies.

In line with the Governance Principles, the Board of Novo Holdings, as the steward of the Foundation’s financial assets, is responsible for managing the Foundation’s shareholding in the operating companies.

So what is the money used for?

In 2024, the Novo Nordisk Foundation awarded around DKK 10 billion for scientific, humanitarian and social purposes. In recent years, we have extended our range of grants considerably, and while Denmark remains our centre of gravity, we also support a growing number of international activities. But what is the money used for? Which activities do we support?

So how does it work?

So what is the money used for?

Published
October 16th, 2024